Kiladjian J-J, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Histomorphological responses after therapy with pegylated interferon О±-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, et al. In conclusion, this study supports treatment of PV with rIFNО± to prevent myelofibrosis and potentially prolong survival. In multivariable analysis, longer time on rIFNО± was associated with a lower risk of myelofibrosis (HR: 0.91, pвЂ‰<вЂ‰0.001) and lower mortality (HR: 0.94, pвЂ‰=вЂ‰0.012). The treatment groups differed by ELN risk score ( pвЂ‰<вЂ‰0.001). The primary treatment was rIFNО± in 93 (20%), HU in 189 (40%), PHL-O in 133 (28%) and other cytoreductive drugs in 55 (12%). Two hundred and twenty-nine patients were women (49%) and 208 were high-risk (44%). The median age at diagnosis was 54 years (range 20вЂ“94) and the median follow-up was 10 years (range 0вЂ“45). This large single center retrospective study of 470 PV patients compares the myelofibrosis-free survival (MFS) and overall survival (OS) with rIFNО± to two other primary treatments, hydroxyurea (HU) and phlebotomy-only (PHL-O). Interferon-alpha (rIFNО±) is the only disease-modifying treatment for polycythemia vera (PV), but whether or not it prolongs survival is unknown.

Interferon alpha pdf